Benjamin F. Edwards & Company’s Arbutus Biopharma ABUS Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$3K	Hold	1,088	–	–	﹤0.01%	1964
2024 Q1	$3K	Hold	1,088	–	–	﹤0.01%	1937
2023 Q4	$3K	Sell	1,088 -3,382	-76%	-$6.62K	﹤0.01%	1924
2023 Q3	$9K	Hold	4,470	–	–	﹤0.01%	1406
2023 Q2	$10K	Sell	4,470 -1,284	-22%	-$3.34K	﹤0.01%	1404
2023 Q1	$17K	Sell	5,754 -4,945	-46%	-$13.9K	﹤0.01%	1296
2022 Q4	$25K	Hold	10,699	–	–	﹤0.01%	1228
2022 Q3	$20K	Hold	10,699	–	–	﹤0.01%	1251
2022 Q2	$29K	Sell	10,699 -732	-6%	-$1.87K	﹤0.01%	1162
2022 Q1	$34K	Sell	11,431 -2,551	-18%	-$7.81K	﹤0.01%	1120
2021 Q4	$54K	Buy	+13,982	New	+$54.3K	﹤0.01%	1028
2021 Q2	–	Sell	-13,900	Closed	-$46K	–	1674
2021 Q1	$46K	Sell	13,900 -2,500	-15%	-$9.65K	﹤0.01%	1028
2020 Q4	$58K	Buy	+16,400	New	+$57.4K	﹤0.01%	931

Other funds holding ABUS

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Benjamin F. Edwards & Company's ABUS Position: Q2 2024 in Review

Benjamin F. Edwards & Company held its Arbutus Biopharma (ABUS) position steady in Q2 2024 at 1,088 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

Benjamin F. Edwards & Company first reported a position in ABUS in Q4 2020 and has held it in 13 quarters since. The position peaked at $58K in Q4 2020. 131 funds tracked by Wall St. Rank hold ABUS as of Q2 2024.

Benjamin F. Edwards & Company held 1,088 shares of Arbutus Biopharma worth $3K as of Q2 2024.
Benjamin F. Edwards & Company left its Arbutus Biopharma share count unchanged in Q2 2024.
Arbutus Biopharma made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1964 holding.
Benjamin F. Edwards & Company first reported a position in Arbutus Biopharma in Q4 2020 and has held it in 13 quarters since.
Benjamin F. Edwards & Company's Arbutus Biopharma position peaked at $58K in Q4 2020.
131 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.